Abstract:Type 2 diabetes is a progressive and complex condition that is difficult to cure in log run. α-Glucosidase inhbitors seems to be most effective in the treatment of diabtes. β-lactams reported for few antidiabetic property with α-glucosidase inhibitory activity. The current study aims at evaluating the potential of newly synthesized β-lactams B8-B14 as α-glucosidase inhibitors which can help in controlling the high blood glucose level in type 2 diabetes mellitus. Herein, the synthesized 3-nitrophenyl imine derivatives (1 eq.) reacted with ethenone (1 eq.) in benzene by staudinger cycloaddition reaction to afford the synthesis of β-lactams B8-B14 and confirmed by advanced spectroscopic techniques and elemental analysis. The antihyperglycemic studies revealed that compounds (B8, B9, B12-B14) at a dosage of 5 mg/kg and after 24 h of administration showed higher percentage of decrease in blood sugar (12.61-21.07%) than reference drug glibenclamide (11.74%). In line with in vitro studies, β-lactams B8 and B9 proved as potent inhibitors of α-glucosidase enzyme with IC50 values 3.33 μM and 2.21 μM respectively higher than standard drug acarbose (IC50= 5.47 μM). Further, in vivo experiment confirmed that the most potent antidiabetic agents B8 and B9 significantly decrease the ALT level (71.1-74.3%) to prevent the liver injury induced by diabetes. The higher antioxidant potential confirmed the role of B9 as lead antidiabetic agent to manage the ROS generated by diabetes. Autodock vina used to identify the catalytic sites of α-glucosidase and to remove water molecules and add hydrogen and kollman charges to protein structure. In molecular docking studies, B9 tightly fit within the catalytic pocket of the α-glucosidase enzyme with a binding affinity of -9.1 kcal/mol that supported its potential as a strong α-glucosidase inhibitor. The most potent compound B9 found to have optimal lipophilicity (2.63), highest druglikeness (86.9%) and excellent gastrointestinal absorption that are suitable for bioavailability and drug design. Moreover these physiochemical properties also showed excellent correlation of to the α-glucosidase inhibitory and antidiabetic activity. Overall, these excellent results suggest that the most potent compound B9 has the potential to develop as a therapeutic drug in the future to treat diabetes with α-glucosidase inhibitory activity.

Synthesis and molecular docking studies of new aryl imeglimin derivatives as a potent antidiabetic agent in a diabetic zebrafish model

Potent α-glucosidase inhibitors with benzimidazole-propionitrile hybridization; synthesis, bioassay and docking study

Synthesis, characterization and molecular modeling approach of hybrid pyrazole based thiazolidinone derivatives: An estimation and inhibition of diabetes mellitus

Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents

Integrative bioinformatic and experimental analysis of benzoylbenzodioxol derivatives: hypoglycemic potential in diabetic mice

Evaluation of novel 2-(quinoline-2-ylthio)acetamide derivatives linked to diphenyl-imidazole as α-glucosidase inhibitors: Insights from in silico , in vitro , and in vivo studies on their anti-diabetic properties

Synthesis, α-Glucosidase, α-Amylase, and Aldol Reductase Inhibitory Activity with Molecular Docking Study of Novel Imidazo[1,2- a ]pyridine Derivatives

Acyl pyrazole sulfonamides as new antidiabetic agents: synthesis, glucosidase inhibition studies, and molecular docking analysis

Investigating the potential of 6-substituted 3-formyl chromone derivatives as anti-diabetic agents using in silico methods

Identification of isobenzofuranone derivatives as promising antidiabetic agents: Synthesis, in vitro and in vivo inhibition of α -glucosidase and α -amylase, computational docking analysis and molecular dynamics simulations

Design, synthesis, in vitro, and in silico anti-α-glucosidase assays of N-phenylacetamide-1,2,3-triazole-indole-2-carboxamide derivatives as new anti-diabetic agents

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies

Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment

A new route to the synthesis of 2-hydrazolyl-4-thiazolidinone hybrids, evaluation of α-glucosidase inhibitory activity and molecular modeling insights

Synthesis, Characterizations, Anti-Diabetic and Molecular Modeling Approaches of Hybrid Indole-Oxadiazole Linked Thiazolidinone Derivatives

Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids

Synthesis and Biological Evaluation of β-lactams as Potent Antidiabetic Agents

Preparation of Novel 3,4,5‐Triaryl‐1,2,4‐Oxadiazole Derivatives: Molecular Docking and α‐Glucosidase assessment

Synthesis and Evaluation of Antidiabetic Potential of Gliptin‐based Hybrid Scaffolds

Synthesis, in vitro potency of inhibition, enzyme kinetics and in silico studies of quinoline-based α-glucosidase inhibitors

Antidiabetic effect of 1-deazapurines derivatives with alpha-glucosidase Enzyme: A molecular tools approach